Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2016 / Articles / May / Hive of Industry
Business & Regulation Business Practice Trends & Forecasts

Hive of Industry

Are you a budding biotech or pharma startup? “The Hive” could be your chance to showcase your work

By James Strachan 05/16/2016 1 min read

Share

Nowadays, more than half of the industry’s drug discoveries originate outside the walls of traditional pharma companies – with many firms supplementing their in-house R&D with external partners. But are the innovative startups responsible for much of the industry’s early drug development getting the exposure they need?

“The Hive” is a project set up by Elsevier R&D Solutions where biotech and pharma startups can apply for the chance to be given a platform to share their work with the wider R&D community, and to receive complimentary access to Elsevier’s tools. Christy Wilson, Senior Director, Pharma and Biotech Segment at Elsevier R&D Solutions, gives us the lowdown. What? The Hive aims to raise the visibility of promising work from biotech and pharma startups, and to share lessons in overcoming pharma R&D challenges with the wider community. Companies need to apply to have their work showcased. Why? The pharmaceutical community is facing a well-documented productivity challenge, and the costs associated with new drug development continue to soar. We think that the wider pharma R&D ecosystem can learn a lot from some of the younger, more nimble organizations. However, such companies can struggle to be heard and a lot of great research goes unnoticed. How? The Hive will publish case studies on successful companies, and we’ll also be sharing work on social media channels. In addition, chosen firms will also receive complimentary access to Elsevier R&D Solutions’ suite of tools; a collection of intelligence and technology tools designed to help improve discovery and development decision making. We also expect some traditional pharma companies to offer some of the innovative startups the capability to further develop and commercialize their innovations. Who? The best candidates for The Hive are biotech and pharmaceutical startups actively working in the early discovery stages through to early stage clinical development. Companies with three or more scientists on staff are ideal. Potential candidates can apply to The Hive themselves or they can be nominated by someone else. Nominated candidates will complete a questionnaire about their research, funding, and goals over the next twelve months; selected candidates will then be invited to participate in a phone interview before the final selection. When? Rolling enrolment for The Hive commenced on April 20, 2016 and will continue throughout the year.

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.